Back to search results
Inactive

Amgen's LabCentral Golden Ticket for innovative life science startups

Deadline: May 1, 2023

Amgen is now accepting submissions from promising start-up companies to compete for two highly sought-after Golden Tickets to LabCentral, which will set the startups with infrastructure, equipment, and services amenities, and services at Cambridge’s premier life sciences launchpad as well as access to Amgen’s network of talent and expertise. The winning start-ups will get an opportunity to be matched with experienced Amgen scientists for a year of mentorship.

All companies with innovative advancements in the cardiovascular and metabolic diseases, oncology, or inflammation therapeutic areas are encouraged to apply, as well as are those focused on making groundbreaking advancements in AI/ML platforms for R&D including data science / protein and generative design, manufacturing innovation, drug delivery, RNA Therapeutics, protein degradation and other proximity biology.

Visit the 2023 Amgen-LabCentral Golden Ticket Competition website for full details and to submit your application by May 1, 2023. 

If you would like to submit an application, please: 

 Apply HERE by May 1, 2023

Deadline: May 1, 2023
Posted on: April 10, 2023
Key Words:
Life Sciences, oncology, Cardiovascular, metabolic, Inflammatory, #AI, #ML, #manufacting #drugdelivery, #RNAtheraeutics

Amgen is now accepting submissions from promising start-up companies to compete for two highly sought-after Golden Tickets to LabCentral, which will set the startups with infrastructure, equipment, and services amenities, and services at Cambridge’s premier life sciences launchpad as well as access to Amgen’s network of talent and expertise. The winning start-ups will get an opportunity to be matched with experienced Amgen scientists for a year of mentorship.

All companies with innovative advancements in the cardiovascular and metabolic diseases, oncology, or inflammation therapeutic areas are encouraged to apply, as well as are those focused on making groundbreaking advancements in AI/ML platforms for R&D including data science / protein and generative design, manufacturing innovation, drug delivery, RNA Therapeutics, protein degradation and other proximity biology.

Visit the 2023 Amgen-LabCentral Golden Ticket Competition website for full details and to submit your application by May 1, 2023. 

If you would like to submit an application, please: 

 Apply HERE by May 1, 2023

Application Requirements


To apply, submit a non-confidential slide deck detailing the following:

  • Your company’s mission
  • Executive Summary (including concept and key differentiators)
  • Upcoming key milestones (including financing)
  • Commercialization/IP strategy
  • Management team/Advisors
  • Anticipated benefits of securing an Amgen–LabCentral Golden Ticket
  • Finalists will be invited to pitch their company to an expert panel of Amgen leaders, as well as an audience including local leaders and venture capitalists at a local in-person event on May 24, 2023.

Questions: GoldenTicket@amgen.com

  • Application Requirements


    To apply, submit a non-confidential slide deck detailing the following:

    • Your company’s mission
    • Executive Summary (including concept and key differentiators)
    • Upcoming key milestones (including financing)
    • Commercialization/IP strategy
    • Management team/Advisors
    • Anticipated benefits of securing an Amgen–LabCentral Golden Ticket
    • Finalists will be invited to pitch their company to an expert panel of Amgen leaders, as well as an audience including local leaders and venture capitalists at a local in-person event on May 24, 2023.

    Questions: GoldenTicket@amgen.com

Disclaimer:  MIT Startup Exchange can make introductions that ideally provide open ended discussions in order to share mutual interests and potentially create common ground that incite the parties to collaborate. MIT Startup Exchange introductions may eventually lead to mutual partnerships, but that is not in any way guaranteed by MIT, MIT Corporate Relations, MIT Industrial Liaison Program (ILP) or MIT Startup Exchange, which takes no responsibility for these outcomes and no formal part in such discussions following our introduction. MIT Startup Exchange and its activities and events are not for purposes of soliciting investment or offering securities.